George Morris, chief operations officer at () tells Proactive the've been given the go-ahead by regulators to expand and accelerate their early-stage cancer study.
The Medicines and Healthcare Regulator Agency and Research Ethics Committee are allowing them to substantially raise the dosing of VAL201, a treatment for metastatic prostate cancer and other solid tumours.
They'll be doing this to find the correct therapeutic levels of treatment to administer in order to try to stop the disease’s spread.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE
